A Multi-center, Open Label, Flexible Dose, Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects With Bipolar I Disorder

Trial Profile

A Multi-center, Open Label, Flexible Dose, Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects With Bipolar I Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Lurasidone (Primary) ; Lithium; Valproate semisodium
  • Indications Bipolar I disorders
  • Focus Adverse reactions
  • Acronyms PERSISTExt
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 06 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov..
    • 12 Mar 2015 Planned End Date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
    • 12 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top